Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
© 2026 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...
Ranked by Dollar volume of Triangle contracts closed in 2025 Ranked by Sale price Miami firm's $87M Durham buy As part of its ongoing commitment to the community, TowneBank appointed six directors to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results